Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
Teva announced the launch of Enoxaparin Sodium Injection, the generic version of Sanofi Aventis‘ Lovenox.
Lovenox is a low molecular weight heparin (LMWH) indicated for prevention of deep vein thrombosis (DVT) in hip or knee replacement surgery, or in abdominal surgery or acutely ill patients with severely restricted mobility at risk for thromboembolism; with warfarin: for inpatient treatment of acute DVT with or without pulmonary embolism (PE), or outpatient treatment of acute DVT without PE; with aspirin: to prevent ischemic complications of unstable angina and non-Q-wave MI; and treatment of acute ST-segment elevation MI (STEMI) managed medically or with subsequent percutaneous coronary intervention (PCI).
RELATED: Thromboembolic Disorder Treatments: DVT/PE
Enoxaparin Sodium Injection is available in 30mg/0.3mL, 40mg/0.4mL, 60mg/0.6mL, 80mg/0.8mL, 100mg/1mL, 120mg/0.8mL, and 150mg/1mL single-dose prefilled syringes in 10-count boxes.
For more information call (888) 838-2872 or visit TevaGenerics.com.
